Azione TNGX TANGO THERAPEUTICS, INC.
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati

Altre lingue Tango Therapeutics, Inc.

Azioni

TNGX

US87583X1090

Tempo reale stimato Cboe BZX
Altri mercati azionari
 17:23:01 03/07/2024 		Variaz. 5gg Var. 1 gen.
8,295 USD +2,34% Grafico intraday di Tango Therapeutics, Inc. -7,05% -16,72%
11/06 Transcript : Tango Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 02:40 PM
28/05 TANGO THERAPEUTICS, INC. : HC Wainwright ribadisce il giudizio positivo sul titolo ZM

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!
Registrazione 100% gratuita
Tango Therapeutics, Inc.(NasdaqGM:TNGX) dropped from Russell 3000E Value Index
Tango Therapeutics, Inc.(NasdaqGM:TNGX) dropped from Russell 3000 Value Index
Tango Therapeutics, Inc.(NasdaqGM:TNGX) dropped from Russell 2500 Value Index
Tango Therapeutics, Inc.(NasdaqGM:TNGX) dropped from Russell Small Cap Comp Value Index
Tango Therapeutics, Inc.(NasdaqGM:TNGX) dropped from Russell 2000 Value Index
Tango Therapeutics : Corporate Presentation
Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Tango Therapeutics Stops Development of USP1 Inhibitor After Liver Toxicity Issues
Sector Update: Health Care Stocks Flat to Lower Premarket Thursday
Sector Update: Health Care
Tango Therapeutics Discontinues TNG348 Program After Showing Liver Toxicity in Trials; Shares Tumble Premarket
Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program
Medivir's licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program
Tango Therapeutics to stop development of cancer therapy
Tango Therapeutics : Corporate Presentation
Tango Therapeutics Announces Discontinuation of TNG348 Program
Tango Therapeutics Announces Discontinuation of TNG348 Program
Tango Appoints Tim Redfern as Chief Financial Officer
Tango Therapeutics : Corporate Presentation
Tango Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione TNGX
  4. Notizie Tango Therapeutics, Inc.
  5. Altre lingue